Overall, our results suggest that ASXL3 could be used as an indicator for drug sensitivity for BET inhibitors, and dBET6 might be a better drug for SCLC treatment in clinical applications, especially for ASXL3-highly expressed SCLC patients. The gene discussed is ASXL3; the disease is small cell lung carcinoma.